Lancet HIV

Article	Citations
COVID-19 in patients with HIV: clinical case series	322
HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform	312
Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19: results from multiple mathematical models	265
Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort	244
Maintaining HIV care during the COVID-19 pandemic	224
The impact of the COVID-19 lockdown on HIV care in 65 South African primary care clinics: an interrupted time series analysis	192
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial	172
Evidence for HIV-1 cure after CCR5Δ32/Δ32 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report	146
Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (	141
HIV and cardiovascular disease	126
Overview of SARS-CoV-2 infection in adults living with HIV	125
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-	115
Associations between HIV infection and clinical spectrum of COVID-19: a population level analysis based on US National COVID Cohort Collaborative (N3C) data	101
Risk factors for COVID-19-related in-hospital mortality in a high HIV and tuberculosis prevalence setting in South Africa: a cohort study	100
SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study	97
Tuberculosis and HIV responses threatened by COVID-19	93
Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial	92
Uptake, engagement, and adherence to pre-exposure prophylaxis offered after population HIV testing in rural Kenya and Uganda: 72-week interim analysis of observational data from the SEARCH study	91
Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferi	84
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study	81
Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: analysis of data from the WHO Global Clinical Platform of COVID-19	81
Three lessons for the COVID-19 response from pandemic HIV	78
Trends in knowledge of HIV status and efficiency of HIV testing services in sub-Saharan Africa, 2000–20: a modelling study using survey and HIV testing programme data	76
Cognitive disorders in people living with HIV	76
Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial	75

Epidemiology of anal human papillomavirus infection and high-grade squamous intraepithelial lesions in 29 900 men according to HIV status, sexuality, and age: a collaborative pooled analysis of 64 stu	75
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, dou	71
Discontinuation, suboptimal adherence, and reinitiation of oral HIV pre-exposure prophylaxis: a global systematic review and meta-analysis	67
Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study	67
Point-of-care HIV viral load testing combined with task shifting to improve treatment outcomes (STREAM): findings from an open-label, non-inferiority, randomised controlled trial	65
Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study	65
HIV outbreaks among people who inject drugs in Europe, North America, and Israel	62
Stigma reduction: an essential ingredient to ending AIDS by 2030	62
Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study	56
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study	56
Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study	55
Adoption of guidelines on and use of oral pre-exposure prophylaxis: a global summary and forecasting study	55
Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study	54
Dolutegravir-associated hyperglycaemia in patients with HIV	52
Global, regional, and national sex-specific burden and control of the HIV epidemic, 1990–2019, for 204 countries and territories: the Global Burden of Diseases Study 2019	52
Long-term protection from HIV infection with oral HIV pre-exposure prophylaxis in gay and bisexual men: findings from the expanded and extended EPIC-NSW prospective implementation study	51
Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study	51
Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospecti	50
The potential effect of COVID-19-related disruptions on HIV incidence and HIV-related mortality among men who have sex with men in the USA: a modelling study	50
Epidemiology of haematological malignancies in people living with HIV	49
Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study	49
Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium	49
Global and regional epidemiology of HIV-1 recombinants in 1990–2015: a systematic review and global survey	48
HCV micro-elimination in individuals with HIV in the Netherlands 4 years after universal access to direct-acting antivirals: a retrospective cohort study	46
Virological failure, HIV-1 drug resistance, and early mortality in adults admitted to hospital in Malawi: an observational cohort study	46
Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies	46
The case for an HIV cure and how to get there	46
Epigenetic age acceleration changes 2 years after antiretroviral therapy initiation in adults with HIV: a substudy of the NEAT001/ANRS143 randomised trial	45
Effect of SMS reminders on PrEP adherence in young Kenyan women (MPYA study): a randomised controlled trial	44
Association of antiretroviral therapy with anal high-risk human papillomavirus, anal intraepithelial neoplasia, and anal cancer in people living with HIV: a systematic review and meta-analysis	44
Defining gaps in pre-exposure prophylaxis delivery for pregnant and post-partum women in high-burden settings using an implementation science framework	43
Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, doubl	42
Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study	42
Ending the HIV epidemic in the USA: an economic modelling study in six cities	42
Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial	41
Financial incentives to promote retention in care and viral suppression in adults with HIV initiating antiretroviral therapy in Tanzania: a three-arm randomised controlled trial	41
Age patterns of HIV incidence in eastern and southern Africa: a modelling analysis of observational population-based cohort studies	41
Multi-stakeholder consensus on a target product profile for an HIV cure	40
Global estimates of viral suppression in children and adolescents and adults on antiretroviral therapy adjusted for missing viral load measurements: a multiregional, retrospective cohort study in 31 c	38
Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial	37
Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study	36
Initiation, discontinuation, and restarting HIV pre-exposure prophylaxis: ongoing implementation strategies	36
Failure to seroconvert after two doses of BNT162b2 SARS-CoV-2 vaccine in a patient with uncontrolled HIV	36
HIV postexposure prophylaxis during COVID-19	35
HIV pre-exposure prophylaxis for men who have sex with men in west Africa: a multicountry demonstration study	34
Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium	33
Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study	32
Estimated life expectancy gains with antiretroviral therapy among adults with HIV in Latin America and the Caribbean: a multisite retrospective cohort study	32
Efficacy of vitamin D3 supplementation for the prevention of pulmonary tuberculosis and mortality in HIV: a randomised, double-blind, placebo-controlled trial	32
Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial	32

Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data	31
Dolutegravir and pregnancy outcomes in women on antiretroviral therapy in Brazil: a retrospective national cohort study	31
Subnational mapping of HIV incidence and mortality among individuals aged 15–49 years in sub-Saharan Africa, 2000–18: a modelling study	31
HIV, chemsex, and the need for harm-reduction interventions to support gay, bisexual, and other men who have sex with men	30
Unified European support framework to sustain the HIV cascade of care for people living with HIV including in displaced populations of war-struck Ukraine	29
PrEP retention and prescriptions for pregnant women during COVID-19 lockdown in South Africa	28
HIV testing approaches to reach the first UNAIDS 95% target in sub-Saharan Africa	28
Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial	27
Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial	27
Addressing the global burden of hepatitis B virus while developing long-acting injectables for the prevention and treatment of HIV	26
Risk compensation and STI incidence in PrEP programmes	26
Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial	26
The risk of mental illness in people living with HIV in the UK: a propensity score-matched cohort study	25
Delayed presentation of HIV among older individuals: a growing problem	25
Same-day prescribing of daily oral pre-exposure prophylaxis for HIV prevention	25
The effect of 90-90-90 on HIV-1 incidence and mortality in eSwatini: a mathematical modelling study	25
Risk of hepatitis C reinfection following successful therapy among people living with HIV: a global systematic review, meta-analysis, and meta-regression	24
Outcomes of donor-derived superinfection screening in HIV-positive to HIV-positive kidney and liver transplantation: a multicentre, prospective, observational study	24
Adolescent participation in HIV research: consortium experience in low and middle-income countries and scoping review	24
PrEP awareness and engagement among transgender women in South Africa: a cross-sectional, mixed methods study	24
Evolving ART crisis for people living with HIV in Indonesia	24
Primary HIV-1 infection in users of pre-exposure prophylaxis	23
How health systems can adapt to a population ageing with HIV and comorbid disease	23
Intertwined epidemics: progress, gaps, and opportunities to address intimate partner violence and HIV among key populations of women	23
Integrating HIV and mental health interventions to address a global syndemic among men who have sex with men	23
Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind,	23
Efficiency of 6-month PrEP dispensing with HIV self-testing in Kenya: an open-label, randomised, non-inferiority, implementation trial	22
COVID-19 in people with HIV	22
End resistance to dolutegravir roll-out	22
Rapid antiretroviral therapy initiation in the Botswana Combination Prevention Project: a quasi-experimental before and after study	21
Perceived HIV stigma and HIV testing among men and women in rural Uganda: a population-based study	21
Effects of implementing universal and rapid HIV treatment on initiation of antiretroviral therapy and retention in care in Zambia: a natural experiment using regression discontinuity	21
Weekly 17 alpha-hydroxyprogesterone caproate to prevent preterm birth among women living with HIV: a randomised, double-blind, placebo-controlled trial	21
Burden of living with HIV among men who have sex with men: a mixed-methods study	20
Fast-tracking the end of HIV in the Asia Pacific region: domestic funding of key population-led and civil society organisations	20
HIV burden and correlates of infection among transfeminine people and cisgender men who have sex with men in Nairobi, Kenya: an observational study	20
Variations in the characteristics and outcomes of children living with HIV following universal ART in sub-Saharan Africa (2006–17): a retrospective cohort study	20
Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17–22)	19
Universal test-and-treat in Zambian and South African correctional facilities: a multisite prospective cohort study	19
When pandemics collide	19
Home-based oral self-testing for absent and declining individuals during a door-to-door HIV testing campaign in rural Lesotho (HOSENG): a cluster-randomised trial	19
Postexposure prophylaxis during COVID-19 lockdown in Melbourne, Australia	19
Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis in HIV epidemics in sub-Saharan Africa: a modelling study	18
Trends and risk of lung cancer among people living with HIV in the USA: a population-based registry linkage study	18
COVID-19 death in people with HIV: interpret cautiously	18
A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial	18
Lockdown fears for key populations	18
Where are the pregnant and breastfeeding women in new pre-exposure prophylaxis trials? The imperative to overcome the evidence gap	18
Prioritising pleasure and correcting misinformation in the era of U=U	18
COVID-19 in patients with HIV	18
HIV clinic-based buprenorphine plus naloxone versus referral for methadone maintenance therapy for treatment of opioid use disorder in HIV clinics in Vietnam (BRAVO): an open-label, randomised, non-in	17
Same-day initiation of oral pre-exposure prophylaxis among gay, bisexual, and other cisgender men who have sex with men and transgender women in Brazil, Mexico, and Peru (ImPrEP): a prospective, singl	17
Associations between punitive policies and legal barriers to consensual same-sex sexual acts and HIV among gay men and other men who have sex with men in sub-Saharan Africa: a multicountry, respondent	17
Tuberculosis screening among HIV-positive inpatients: a systematic review and individual participant data meta-analysis	17
Costs and impact on HIV transmission of a switch from a criminalisation to a public health approach to injecting drug use in eastern Europe and central Asia: a modelling analysis	16
HIV care cascade and associated factors among men who have sex with men, transgender women, and genderqueer individuals in Zimbabwe: findings from a biobehavioural survey using respondent-driven sampl	16
Long-acting antiretrovirals and HIV treatment adherence	16
Population uptake of HIV testing, treatment, viral suppression, and male circumcision following a community-based intervention in Botswana (Ya Tsie/BCPP): a cluster-randomised trial	16
Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and th	16
Temporal change in population-level prevalence of detectable HIV viraemia and its association with HIV incidence in key populations in India: a serial cross-sectional study	15
Incorporating oral PrEP into standard prevention services for South African women: a nested interrupted time-series study	15
Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-infer	15
Free HIV self-test for identification and linkage to care of previously undetected HIV infection in men who have sex with men in England and Wales (SELPHI): an open-label, internet-based, randomised c	15
HIV treatment-as-prevention and its effect on incidence of HIV among cisgender gay, bisexual, and other men who have sex with men in Australia: a 10-year longitudinal cohort study	14
Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1–2 trial	14
Haemopoietic cell transplantation in patients living with HIV	14
72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study	13
Implementation and outcomes of dolutegravir-based first-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study	13
The HIV-1 antibody response: a footprint of the viral reservoir in children vertically infected with HIV	13
Framework for the implementation of advanced HIV disease diagnostics in sub-Saharan Africa: programmatic perspectives	13
A Bayesian averted infection framework for PrEP trials with low numbers of HIV infections: application to the results of the DISCOVER trial	13
Kidney function in tenofovir disoproxil fumarate-based oral pre-exposure prophylaxis users: a systematic review and meta-analysis of published literature and a multi-country meta-analysis of individua	13
Cost-effectiveness of point-of-care testing with task-shifting for HIV care in South Africa: a modelling study	13
Scaling up access to HIV pre-exposure prophylaxis (PrEP): should nurses do the job?	13
Estimates of the prevalence of undiagnosed HIV among children living with HIV in Eswatini, Lesotho, Malawi, Namibia, Tanzania, Zambia, and Zimbabwe from 2015 to 2017: an analysis of data from the cros	13
Modern diagnostic technologies for HIV	13
Outcomes of people living with HIV after hospital discharge: a systematic review and meta-analysis	13
Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study	12
A tale of four studies: HIV vaccine immunogenicity and efficacy in clinical trials	12
Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept study	12

Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial	12
Alignment of PrEP adherence with periods of HIV risk among adolescent girls and young women in South Africa and Zimbabwe: a secondary analysis of the HPTN 082 randomised controlled trial	12
Protease inhibitor-based antiretroviral therapy in pregnancy: effects on hormones, placenta, and decidua	12
Hypogonadism and bone health in men with HIV	12
The effects of intimate partner violence on women's risk of HIV acquisition and engagement in the HIV treatment and care cascade: a pooled analysis of nationally representative surveys in sub-Saharan	12
Novel metric for evaluating pre-exposure prophylaxis programme effectiveness in real-world settings	12
HIV incidence and mortality in transgender women in the eastern and southern USA: a multisite cohort study	11
Adolescent retention in HIV care within differentiated service-delivery models in sub-Saharan Africa	11
Status of the HIV epidemic in key populations in the Middle East and north Africa: knowns and unknowns	11
Messaging matters: achieving equity in the HIV response through public health communication	11
Tracking elimination of HIV transmission in men who have sex with men in England: a modelling study	11
Epidemiology of severe COVID-19 from South Africa	11
The future of HIV pre-exposure prophylaxis adherence: reducing barriers and increasing opportunities	11
Disparities in breast cancer survival between women with and without HIV across sub-Saharan Africa (ABC-DO): a prospective, cohort study	11
Health system adaptations and considerations to facilitate optimal oral pre-exposure prophylaxis scale-up in sub-Saharan Africa	11
Multimonth dispensing of antiretroviral therapy for HIV	11
Adult HIV-1 incidence across 15 high-burden countries in sub-Saharan Africa from 2015 to 2019: a pooled analysis of nationally representative data	11
Trends in suicide mortality among people with HIV after diagnosis during 2012–18: a retrospective, national cohort study in China	11
Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial	11
HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis	11
Two-drug regimens for HIV treatment	10
Cancer risk in adolescents and young adults living with HIV in South Africa: a nationwide cohort study	10
More evidence for worse COVID-19 outcomes in people with HIV	10
Long-term virological outcomes in women who started option B+ care during pregnancy for prevention of mother-to-child transmission of HIV in Dar es Salaam, Tanzania: a cohort study	10
HIV-related stigma among health-care workers in the MENA region	10
The effect of providing women sustained access to HIV self-tests on male partner testing, couples testing, and HIV incidence in Kenya: a cluster-randomised trial	10
Associations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study	10
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial	10
Trends in HIV testing, the treatment cascade, and HIV incidence among men who have sex with men in Africa: a systematic review and meta-analysis	10
Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial	10